Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records
- Yayoi Nishida†1, 2,
- Yasuo Takahashi†1, 2,
- Tomohiro Nakayama†3,
- Masayoshi Soma†4,
- Noboru Kitamura†5 and
- Satoshi Asai†1, 2Email author
© Nishida et al; licensee BioMed Central Ltd. 2010
Received: 27 May 2010
Accepted: 16 August 2010
Published: 16 August 2010
Studies focusing on the add-on effects of angiotensin II type 1 receptor blockers (ARBs) other than their antihypertensive effect are receiving attention. However, the effects of prolonged administration of ARBs on lipid metabolism in clinical cases are unclear. Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan.
We carried out candesartan monotherapy in patients with mild to moderate hypertension and examined the longitudinal changes in plasma lipid profile. Data from 405 patients for triglyceride (TG), 440 for total cholesterol (TC), 313 for high density lipoprotein cholesterol (HDL-C) and 304 for low density lipoprotein cholesterol (LDL-C) were obtained from the electronic medical records (EMRs) in the Clinical Data Warehouse (CDW) of Nihon University School of Medicine (NUSM). The inverse probability of treatment weighting (IPTW) method (calculated from the inverse of the propensity score) was used to balance the covariates and reduce bias in each treatment duration. Linear mixed effects models were used to analyse the relationship between these longitudinal data of blood examinations and covariates of patient sex, age, diagnosis of diabetes mellitus (DM) and duration of candesartan monotherapy.
Plasma HDL-C level was associated with sex, duration of treatment, and interaction of sex and treatment duration, but not with age or diagnosis of DM. HDL-C level was significantly decreased during the 6~9 months period (p = 0.0218) compared with baseline. TG and TC levels were associated with sex, but not with age, diagnosis of DM or treatment duration. LDL-C level was not associated with any covariate. Analysis of the subjects divided by sex revealed a decrease in HDL-C in female subjects (during the 6~9 months period: p = 0.0054), but not in male subjects.
Our study revealed that administration of candesartan slightly decreased HDL-C in female subjects. However, TG, TC and LDL-C levels were not influenced by candesartan monotherapy. Candesartan may be safely used for patients with hypertension with respect to lipid metabolism, because the effect of candesartan on lipids may be small.
Candesartan cilexetil is a selective angiotensin II type I receptor blocker (ARB). It is known that some ARBs improve insulin resistance , and we reported that monotherapy with ARBs including candesartan had a favorable effect on glucose metabolism . Previous clinical trials showed that candesartan-based treatment reduced non-fatal strokes in elderly hypertensive patients , and that a 7-day course of candesartan after an acute ischaemic stroke significantly improved cardiovascular morbidity and mortality . Pfeffer et al. reported that administration of candesartan to patients with chronic heart failure improved cardiovascular morbidity and mortality . These large-scale clinical trials suggested the possibility that candesartan has an add-on effect to reduce cardiovascular risk. Meanwhile, an animal study showed that candesartan increased peroxisome proliferator-activated receptor-γ (PPAR-γ) mRNA expression and serum adiponectin level . Therefore, it has been suggested that candesartan has a potential effect on lipid metabolism. A recent clinical study on the effect of candesartan on lipid metabolism showed that total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels were significantly decreased in hypertensive patients administered candesartan for at least 6 months . However, the effects of prolonged administration of candesartan on lipid metabolism in patients are unclear.
In this study, we carried out candesartan monotherapy in patients, examined the longitudinal changes in plasma lipid profile up to 12 months, and studied the correlation between the profile and the duration of administration.
Our main explanatory variables included sex, age at start of treatment, diagnosis of DM, and "duration" defined as the timing of measurement in days since the start of treatment as follows; baseline (within 3 months before start of treatment), 0~3 M (>0, ≤3 months), 3~6 (>3, ≤6 months), 6~9M (>6, ≤9 months) and 9~12 M (>9, ≤12 months). Our main response variables were repeated measurements of TG, TC, HDL-C and LDL-C levels in blood before and after candesartan cilexetil monotherapy. These data were not randomized, and were inherently unbalanced because the number and timing of the repeated measurements were different among individuals. The composition of the patients and the number of examinations were not equal for each of the treatment durations, and may have been time-dependently affected by candesartan monotherapy itself. Marginal structural models using inverse probability of treatment weighting (IPTW) have been recently developed to solve this problem that the treatment effects are affected by time-dependent confounders that are themselves affected by the treatment . Therefore, we used IPTW to balance the treatment durations so as to reduce bias in the patient background and obtain a better idea of the effect of treatment on the outcome of compliance. IPTW is calculated as the inverse of the propensity score. The propensity score method introduced by Rosenbaum and Rubin is an effective tool to reduce bias in nonrandomized studies including unbalanced data . The traditional propensity score method such as matching, stratification and covariance adjustment is mostly used in binary-value treatment [11–13]. Recently, there have been many reports trying to expand its application to more than two treatments [14–16]. We referred to the method introduced by Leslie et al., and used an IPTW-linear mixed effect model to reduce bias in the duration of treatment [15–18]. This method consisted of three steps as follows. As the first step, we used propensity score adjustment to account for potential selection bias in each treatment duration. We used a logistic regression model to calculate the propensity score as the probability of examinations with each treatment duration. The variables in this step included sex, age and diagnosis of DM. As the second step, IPTW was calculated as the inverse of the propensity score. By using this IPTW in the next step, bias in each treatment duration could be minimized. To give more weight to smaller treatment groups, a weight was created that reflects the sample size for each blood examination. As the third step, an IPTW-linear mixed effect model was fitted to analyse the relationship between these longitudinal data of blood examinations and all other covariates. We fitted repeated measurement analysis (covariance structure: Compound Symmetry) to the data, including sex, age, diagnosis of DM and a confounding factor of interaction of sex and duration of treatment as fixed effect covariates, and duration of treatment as a repeated effect covariate. We selected the Kenward-Roger method to compute the denominator degrees of freedom for the tests of fixed effects. A multiple-comparison test (Dunnett-Hsu post-hoc analysis) was used to compare the differences in means between "baseline" as a reference and other treatment duration periods. A result was considered statistically significant if the p value was less than 0.05. All statistical analysis was performed with SAS 9.1.3 (SAS Institute Inc., Cary, NC) statistical software.
Characteristics of study sample
Frequency distribution of blood examination data.
Number of patients
Mean ± SE
61.2 ± 14.5
61.7 ± 14.9
60.3 ± 14.6
60.2 ± 14.4
20 - 86
20 - 91
20 - 86
20 - 86
Sex, number (%)
DM, number (%)
Data information (number of examinations)
Relationship of covariates to plasma lipid profile
Relationship of covariates to plasma lipid profile
Multiple comparison test of levels of lipid parameters among treatment duration periods.
LS mean ± SE
LS mean ± SE
1.51 ± 0.05
5.30 ± 0.04
1.52 ± 0.07
5.24 ± 0.05
1.53 ± 0.07
5.30 ± 0.06
1.61 ± 0.08
5.26 ± 0.06
1.54 ± 0.08
5.34 ± 0.07
LS mean ± SE
LS mean ± SE
1.47 ± 0.02
3.12 ± 0.05
1.45 ± 0.03
3.10 ± 0.05
1.45 ± 0.03
3.05 ± 0.06
1.40 ± 0.03
3.11 ± 0.06
1.41 ± 0.03
3.08 ± 0.07
Multiple comparison test of HDL-C level among treatment duration periods, by sex.
Female HDL-C (nmol/L)
Male HDL-C (nmol/L)
LS mean ± SE
LS mean ± SE
1.57 ± 0.04
1.38 ± 0.04
1.51 ± 0.04
1.40 ± 0.03
1.56 ± 0.04
1.36 ± 0.03
1.45 ± 0.05
1.37 ± 0.04
1.47 ± 0.06
1.36 ± 0.04
In this study, we examined the changes in laboratory data of lipid metabolism up to 12 months in patients receiving candesartan monotherapy. Because this survey was a longitudinal study, the study population represented its own time-related control group. In this retrospective longitudinal survey, we found a significant reduction in HDL-C level from the start to 6~9 months of candesartan administration (Tables 2 and 3). These results suggest that candesartan has an unfavorable effect on lipid metabolism, with a reduction in HDL-C level by administration of candesartan for 6~9 months in female subjects. However, the effect of candesartan to reduce HDL-C level was transient and limited to female subjects. Moreover, HDL-C level was within the normal range throughout the study period (Table 4). Therefore, this slightly unfavorable effect of candesartan monotherapy on HDL-C in female subjects may not be a problem in clinical practice. Regarding lipid metabolism, candesartan may be safely used for patients with hypertension in the long term up to 12 months. Bramlage et al. reported that ARBs provide substantial cost savings and may prevent cardiovascular morbidity and mortality based on more complete antihypertensive coverage, suggesting that ARBs are an attractive choice for long-term treatment of hypertension . Our findings on the safety of long-term use of candesartan with respect to lipid metabolism reinforce these benefits of ARBs.
Only a few studies have examined the effect of candesartan on lipid metabolism; however, some showed that administration of candesartan had no effect on lipid metabolism. When HDL-C, TC, and TG levels were compared between before administration and after 2 weeks of candesartan administration to patients with essential hypertension, no significant difference was found . Also, when HDL-C, LDL-C, TC, and TG levels were compared between before administration and after 8 weeks of candesartan administration to patients with mild hypertension and type 2 DM, no significant difference was found . When HDL-C, LDL-C, TC, and TG levels were compared between before administration and after 12 weeks of candesartan administration to patients with mild hypertension and type 2 DM, no significant difference was found . Furthermore, when HDL-C, LDL-C, TC, and TG levels were compared between before administration and after 12 months of candesartan administration to patients with mild hypertension and type 2 DM, no significant difference was found . Supporting these previous reports, no significant changes were observed with candesartan administration for less than 6 months and more than 9 months in our study.
A close relationship has been suggested between lipid and glucose metabolism, but there was no association between lipid metabolism and the covariate of DM in our study results (Table 2). The reason for this may be that only patients with well-controlled blood glucose were selected during the subject selection stage in this study, because patients with a very high HbA1c level (≥8.0%) were excluded. As a result, there was a smaller effect of glucose metabolism abnormality on lipid metabolism.
In our study, HDL-C level was significantly reduced in female subjects, but not in male subjects (Figure 2 and Table 4). The reason for this discrepancy may be as follows. First, the effect of candesartan on HDL-C may be stronger in patients with a high HDL-C level than in those with a low HDL-C level. It is well known that there is a sex-difference in plasma lipid profile; plasma HDL-C level is generally higher in female subjects than in male subjects [24, 25]. Second, the effect of candesartan on HDL-C may reflect its effects on hormones. A previous report revealed that oestrogen increases HDL-cholesterol . However, the reason for this discrepancy between male and female subjects is still unclear.
This study was a retrospective database study, which can provide many benefits as follows: First, real-time data can be provided quickly and cost-effectively. Second, the sample sizes are relatively large. Third, the influences on the patients' risk are minimal. These strengths readily led to stimulating studies and promising outcomes . On the other hand, our study was a retrospective observational study, which has some limitations with respect to the potential for selection bias and confounding factors. However, these problems caused by non-randomized data could be solved by combination with robust statistics; for example, propensity score method . Our study, with appropriate application of statistical analysis techniques; i.e., the propensity score adjustment and weighted-linear mixed model, may yield findings with validity, and help physicians make decisions on drug selection.
In this study, we examined the effect of candesartan monotherapy on lipid metabolism. Our results revealed that HDL-C level in female subjects declined from 6 to 9 months after the initiation of candesartan monotherapy. However, the reduction of HDL-C level was transient and was observed only in female subjects. Moreover, the HDL-C level was within the normal range throughout the study period. In addition, TG, TC and LDL-C levels were not influenced by candesartan monotherapy. These results indicate a lack of obvious evidence showing an unfavorable influence of candesartan on lipid metabolism. Therefore, the influence of candesartan monotherapy on lipid metabolism may be small and may not be a clinical problem. In the field of lipid metabolism, candesartan may be safely used for patients with hypertension.
This work was supported in part by Tempstaff Co., Ltd. (Tokyo, Japan).
- Doggrell SA: Telmisartan - killing two birds with one stone. Expert Opin Pharmacother. 2004, 5: 2397-2400. 10.1517/146565126.96.36.1997.View ArticlePubMedGoogle Scholar
- Kitamura N, Takahashi Y, Yamadate S, Asai S: Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol. 2007, 6: 26-10.1186/1475-2840-6-26.PubMed CentralView ArticlePubMedGoogle Scholar
- Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A, SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003, 21: 875-886. 10.1097/00004872-200305000-00011.View ArticlePubMedGoogle Scholar
- Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group: The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003, 34: 1699-1703. 10.1161/01.STR.0000075777.18006.89.View ArticlePubMedGoogle Scholar
- Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003, 362: 759-766. 10.1016/S0140-6736(03)14282-1.View ArticlePubMedGoogle Scholar
- Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM: Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol. 2006, 552: 112-122. 10.1016/j.ejphar.2006.08.062.PubMed CentralView ArticlePubMedGoogle Scholar
- Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI: Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol. 2006, 47: 21-28.PubMedGoogle Scholar
- Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C, Shima K, Nonaka K, Kadowaki T, Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002, 55: 65-85. 10.1016/S0168-8227(01)00365-5.View ArticlePubMedGoogle Scholar
- Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U: Good research practices for comparative effectiveness research: analytic method to improve casual inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report-part III. Value Health. 2009, 12: 1062-1073. 10.1111/j.1524-4733.2009.00602.x.View ArticlePubMedGoogle Scholar
- Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika. 1983, 70: 41-55. 10.1093/biomet/70.1.41.View ArticleGoogle Scholar
- Kang DH, Park SJ, Rim JH, Yun SC, Kim DH, Song JM, Choo SJ, Park SW, Song JK, Lee JW, Park PW: Early surgery versus conventional treatment in asymptomatic very severe aortic stenosis. Circulation. 2010, 121: 1502-1509. 10.1161/CIRCULATIONAHA.109.909903.View ArticlePubMedGoogle Scholar
- Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA: Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005, 352: 2174-2183. 10.1056/NEJMoa040316.View ArticlePubMedGoogle Scholar
- Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB: Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002, 346: 822-9. 10.1056/NEJMsa003087.View ArticlePubMedGoogle Scholar
- Imbens GW: The role of the propensity score in estimating dose-response functions. Biometrika. 2000, 87: 706-710. 10.1093/biomet/87.3.706.View ArticleGoogle Scholar
- Patel BV, Leslie RS, Thiebaud P, Nichol MB, Tang SS, Solomon H, Honda D, Foody JM: Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008, 4: 673-681.PubMed CentralPubMedGoogle Scholar
- Linden A, Adams JL: Evaluation health management programmes over time: application of propensity score-based weighting to longitudinal data. J Eval Clin Pract. 2010, 16: 180-185. 10.1111/j.1365-2753.2009.01361.x.View ArticlePubMedGoogle Scholar
- Leslie S, Thiebaud P: Using propensity score to adjust for treatment selection bias. SAS Global forum. 2007, [http://www2.sas.com/proceedings/forum2007/184-2007.pdf] paper 184-2007Google Scholar
- D'Agostino R: Tutorial on Biostatistics: Propensity Score Methods for Bias Reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998, 17: 2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B.View ArticlePubMedGoogle Scholar
- Bramlage P, Hasford J: Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. Cardiovasc Diabetol. 2009, 8: 18-10.1186/1475-2840-8-18.PubMed CentralView ArticlePubMedGoogle Scholar
- Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003, 42: 76-81. 10.1161/01.HYP.0000078490.59735.6E.View ArticlePubMedGoogle Scholar
- Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, Shin EK: Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010, 140: 73-81. 10.1016/j.ijcard.2008.11.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Trenkwalder P, Dahl K, Lehtovirta M, Mulder H: Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes. Blood Press. 1998, 7: 170-175. 10.1080/080370598437385.View ArticlePubMedGoogle Scholar
- Derosa G, Cicero AF, Ciccarelli L, Fogari R: A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther. 2003, 25: 1006-1021.Google Scholar
- National Cholesterol Education Program (NCEP) Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421.Google Scholar
- Sutherland WH, Temple WA, Nye ER, Herbison GP: Adiposity, lipids, alcohol consumption, smoking, and gender. Am J Clin Nutr. 1980, 33: 2581-2587.PubMedGoogle Scholar
- The writing group for PEPI trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995, 273: 199-208. 10.1001/jama.273.3.199.View ArticleGoogle Scholar
- Arnold RG, Kotsanos JG: Panel 3: methodological issues in conducting pharmacoeconomic evaluations--retrospective and claims database studies. Value Health. 1999, 2: 82-87. 10.1046/j.1524-4733.1999.02204.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.